Compare TATT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TATT | PRTA |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | Israel | Ireland |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.2M | 495.8M |
| IPO Year | 1987 | N/A |
| Metric | TATT | PRTA |
|---|---|---|
| Price | $52.19 | $9.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $48.40 | $18.86 |
| AVG Volume (30 Days) | 184.5K | ★ 683.2K |
| Earning Date | 11-12-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.30 | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $172,525,000.00 | $11,786,000.00 |
| Revenue This Year | $20.38 | N/A |
| Revenue Next Year | $17.20 | $1,183.79 |
| P/E Ratio | $39.48 | ★ N/A |
| Revenue Growth | ★ 20.72 | N/A |
| 52 Week Low | $23.37 | $4.32 |
| 52 Week High | $53.59 | $16.67 |
| Indicator | TATT | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 71.83 | 48.04 |
| Support Level | $51.00 | $8.65 |
| Resistance Level | $52.83 | $9.34 |
| Average True Range (ATR) | 2.06 | 0.36 |
| MACD | 0.26 | 0.04 |
| Stochastic Oscillator | 86.12 | 69.71 |
TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.